Literature DB >> 32663995

Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.

G Fond1, T Korchia2, P L Sunhary de Verville3, O Godin3, F Schürhoff4, F Berna5, M André6, B Aouizerate7, D Capdevielle6, I Chereau8, T D'Amato9, C Dubertret10, J Dubreucq11, S Leignier11, J Mallet10, D Misdrahi12, C Passerieux13, B Pignon4, R Rey9, A Szoke4, M Urbach13, P Vidailhet14, M Leboyer4, P M Llorca8, C Lançon2, L Boyer2.   

Abstract

BACKGROUND: Impaired Quality of life (QoL) in schizophrenia has been mostly associated with psychotic and mood symptomatology, insight and functioning so far. AIMS: QoL levels remain unsatisfactory due to other factors we aim to explore.
METHOD: We have explored sleep quality with the Pittsburgh Sleep Quality Index, hostility with the Buss&Perry questionnaire, major depression with the Positive and Negative Syndrome Scale depressive factor, functioning with the Global Assessment of Functioning scale and weight gain with body mass index in addition to other classical QoL-associated factors.
RESULTS: 559 patients (mean age=31 (SD 9) years, 74% male sex) were included in the national FACE-SZ cohort. Impaired QoL has been significantly associated with respectively major depression, impaired sleep quality, increased hostility, impaired functioning and impaired insight independently of age, sex, treatments, tobacco smoking and body mass index. Major depression was associated with impaired psychological and physical well-being, and impaired self-esteem. Impaired sleep quality has been associated with impaired psychological and physical well-being and sentimental life. Hostility has been associated with impaired psychological well-being and self-esteem, impaired friends' relationships and impaired autonomy. Weight was associated with impaired physical well-being. Tobacco smoking was associated with higher level of friends' relationships.
CONCLUSIONS: Major depression, sleep, hostility, and weight gain have been identified as potential targets to improve QoL in schizophrenia and should be implemented in the recommendations for good practice to optimize schizophrenia care.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hostility; Major depression; Psychiatry; Quality of life; Schizophrenia; Sleep quality; Weight

Mesh:

Year:  2020        PMID: 32663995     DOI: 10.1016/j.jad.2020.05.003

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  3 in total

1.  Overlap and Mutual Distinctions Between Clinical Recovery and Personal Recovery in People With Schizophrenia in a One-Year Study.

Authors:  Julien Dubreucq; Franck Gabayet; Ophélia Godin; Myrtille Andre; Bruno Aouizerate; Delphine Capdevielle; Isabelle Chereau; Julie Clauss-Kobayashi; Nathalie Coulon; Thierry D'Amato; Jean-Michel Dorey; Caroline Dubertret; Mégane Faraldo; Hakim Laouamri; Sylvain Leigner; Christophe Lancon; Marion Leboyer; Pierre-Michel Llorca; Jasmina Mallet; David Misdrahi; Christine Passerieux; Romain Rey; Baptiste Pignon; Benoit Schorr; Mathieu Urbach; Franck Schürhoff; Andrei Szoke; Guillaume Fond; Fabrice Berna
Journal:  Schizophr Bull       Date:  2022-03-01       Impact factor: 9.306

2.  Effectiveness of using calligraphic activity to treat people with schizophrenia: a randomized controlled trial in Southern Taiwan.

Authors:  Wen-Yi Huang; Hector W H Tsang; Shu-Mei Wang; Yu-Chen Huang; Yi-Chun Chen; Chih-Heng Cheng; Chih-Yin Chen; Jung-Sheng Chen; Yen-Ling Chang; Ru-Yi Huang; Chung-Ying Lin; Marc N Potenza; Amir H Pakpour
Journal:  Ther Adv Chronic Dis       Date:  2022-03-11       Impact factor: 5.091

3.  Quality of life in patients with schizophrenia: A 2-year cohort study in primary mental health care in rural China.

Authors:  Xiao-Yan He; Christine Migliorini; Zhuo-Hui Huang; Fei Wang; Rui Zhou; Zi-Lang Chen; Yao-Nan Xiao; Qian-Wen Wang; Shi-Bin Wang; Carol Harvey; Cai-Lan Hou
Journal:  Front Public Health       Date:  2022-09-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.